The non-cell-permeable HSP90 inhibitor HS30 significantly inhibited eHSP90α and LRP1 colocalization, which was significantly increased in patients with moderate and severe IPF. Here, HSP90AA1 is linked to idiopathic pulmonary fibrosis.